It’s back to school for biotech, with a packed conference schedule.

Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer. 

A statistical analysis of Skyscraper-01’s second interim read is inadvertently posted on a Roche website.